Optimizing enfortumab vedotin plus pembrolizumab therapy

TL;DR

This paper reviews the progress in treating advanced urothelial carcinoma, focusing on a new effective combination therapy involving enfortumab vedotin and pembrolizumab.

Contribution

The paper highlights the introduction of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma.

Findings

The combination of enfortumab vedotin and pembrolizumab improves survival rates in advanced urothelial carcinoma.

EV-302 trial results support the use of this combination as a first-line therapy.

Abstract

Often associated with a poor prognosis, advanced urothelial carcinoma (aUC) has progressed to muscle-invasive or metastatic stages. Traditionally, chemotherapy has been the primary treatment for aUC, though its effectiveness in advanced stages remains limited. Recent developments have introduced promising therapies, notably the combination of enfortumab vedotin with pembrolizumab, which is now recommended as the first-line therapy following the EV-302 trial results. This combination has demonstrated significant improvements in survival rates. This review aims to explore the evolution of treatment strategies for aUC, emphasizing the shift towards immunotherapy and targeted therapies, and discusses the potential for optimized treatment algorithms to improve patient outcomes.

Figures